2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Abatacept
- PMID: 40923137
- DOI: 10.1093/cid/ciaf354
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Abatacept
Abstract
This article provides a focused update to the clinical practice guideline on the treatment and management of patients with coronavirus disease 2019 (COVID-19), developed by the Infectious Diseases Society of America. The guideline panel presents a recommendation on the use of abatacept in hospitalized adults with severe or critical COVID-19. The recommendation is based on evidence derived from a systematic literature review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach.
Keywords: COVID-19; SARS-CoV-2; abatacept; guideline.
© The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
Conflict of interest statement
Potential conflicts of interest. Evaluation of relationships as potential conflicts of interest (COI) is determined by a review process. The assessment of disclosed relationships for possible COIs is based on the relative weight of the financial relationship (ie, monetary amount) and the relevance of the relationship (ie, the degree to which an association might reasonably be interpreted by an independent observer as related to the topic or recommendation of consideration). No panelists had COIs directly related to abatacept. The following panelists have scientific advisory/consultant roles not related to the topic of COVID-19 with indicated companies: R. B. with Merck and Gilead, E. S. D. with Gilead, D. V. G. with Merck and Gilead, S. S. with Pfizer (concluded), P. T. with Merck, and R. G. with Merck. The following panelists have scientific advisory/consultant roles related to COVID-19 but not severe/critical COVID-19 with indicated companies: R. B. with Shionogi, K. C. with Pardes Biosciences (concluded), A. Y. K. with Shionogi, S. S. with Adamis and Immunome (concluded), and P. T. with Shionogi. J. C. P. had a scientific advisory/consultant role (concluded) with InflaRx related to vilobelimab for critical COVID-19. No disclosures were reported for all other authors (the majority of panelists), including chair and vice chair. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous